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Introduction and overview
The secondary causes of osteoporosis are frequent but be-
cause of the vast numbers of women suffering from post-
menopausal and age related bone loss and fractures, its impor-
tance is overshadowed despite the fact that these forms of os-
teoporosis can be potentially devastating. With this in mind the
1st International Symposium on Secondary Causes of Osteo-
porosis was held in July 2006 in Florence, Italy. The invited
speakers were all international authorities on their subject and
presented new data derived from their own research and the
world literature. There were 6 sessions in all. 
The first session covered immune related bone disease and the
emerging field of immuno-osteobiology. The topics reviewed in-
cluded the role of T cells in mediating the action of PTH, the ex-
citing discovery that the osteocytes and their canaliculi are dis-
rupted by glucocorticoid excess which may help explain the poor
bone quality in steroid induced osteoporosis. The role of the cal-
cineurin inhibitors on bone in post transplant induced bone dis-
ease and the role of the T lymphocytes and new treatment
modalities for this devastating form of osteoporosis was dis-
cussed. A form of osteoporosis which is emerging as an impor-
tant consideration for both men and women is cancer therapy
with the increasing use of aromatase inhibitors and androgen
deprivation therapy for the treatment of breast and prostate can-
cer. The fracture rate is increased and bisphosphonates are the
mainstay of standard of care for the bone problems despite the
potential for osteonecrosis of the jaw in these patients. 
The second session concentrated on gastrointestinal, rheumat-
ic, renal and neurological diseases.
The inflammatory bowel diseases produce osteoporosis via a
variety of mechanisms, including inflammatory cytokines, dis-
turbances of the RANKl/OPG system, malnutrition and Vitamin
D deficiency. Rheumatoid arthritis patients have an increased
risk of fracture due to steroid medication as well as alterations
in the RANKL/OPG system. The risk of fracture is also in-
creased in ankylosing spondylitis. Treatment modalities include
bisphosphonates and disease modifying drugs such as anti-
TNF therapies. Uremic osteodystrophy and the various meta-
bolic abnormalities relating to PTH, Vitamin D, phosphate re-
tention and the complex interplay resulting in the different types
of bone abnormalities and new therapies such as the Vitamin D
analogs and calcimimetics were also discussed.
The final topic of this session was the effect of immobilization
stroke and spinal cord injuries on bone loss. The severity of
bone loss with immobilization is much greater than that seen
with post menopausal osteoporosis as are fracture rates. Both
trabecular and cortical bone are lost. The main etiology is loss
of mechanical stimulation. Therapy is largely still unproven and
the studies have not been powered sufficiently to assess frac-
ture rates. 
The third session which generated a lot of debate was that
which was devoted to “hot” topics which were not well publi-
cized but increased our understanding of osteoporosis in cer-
tain populations. Anorexia nervosa has an incidence of os-
teopenia of 90% and osteoporosis of 40% with a 7-fold in-
crease in fracture rate. Here the main brunt of the disease was
on the osteoblast with bone formation impaired although bone
resorption is also increased. Etiological factors include a GH
(growth hormone) resistant state, estrogen deficiency, calcium
and vitamin D abnormalities as well as hypercortisolism and
nutritional/regulated hormones. The treatment is difficult and no
therapy has been shown to be ideal in reversing the bone loss.
The role of anabolics, estrogen and IGF1 singly or in combina-
tion was discussed. 
Weightlessness (lack of gravity) during space flight have in-
trigued bone researchers particularly as space flights are be-
coming more common, and of longer duration. The principal
cause appears to be loss of mechanical signals to the skeleton.
This loss occurs despite 2 hours exercise per day. A novel ap-
proach maybe to exert low magnitude/high frequency loading
regimens via mechanical devices. These appear to be effective
in delivering signals to the bony skeleton as well as to the mus-
cular components of the skeleton.
The role of idiopathic hypercalciuria,  osteoporosis and the role
of cytokines such as IL-1, IL-6, and TNF alpha in the pathogen-
esis were discussed. The type of osteoporosis is one of in-
creased bone resorption. Thiazide diuretics are still the main-
stay of treatment to reduce the hypercalciuria.
Vitamin D plays an integral role in skeletal integrity yet more
than 50% of postmenopausal women worldwide and 97% of
hospitalized patients in some countries have Vitamin D levels
below 30 ng/ml (75 nmol/L). This level by consensus is consid-
ered sufficient or adequate. The other functions of Vitamin D
were discussed (eg, in relationship to falls, musculoskeletal in-
tegrity and immunity, etc.). 
Session 4 included osteoporotic fractures in men. These are
an important public health problem. The fracture burden is
about 1/3 that of post menopausal osteoporotic women. The
morbidity and mortality may exceed that of their female coun-
terparts with hip fractures. Gender affects on the anatomy of
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the skeleton plays a role with men having thicker cortices and
larger bones. Osteoporosis in men is often idiopathic but is
also multifactorial with the role of the sex steroids now begin-
ning to be clarified. BMD still remains an integral part of the
identification of men at risk for fracture. Despite tools for mea-
suring BMD few men are diagnosed and treated for osteo-
porosis.
The last talk of this session was an extremely comprehensive
presentation of the practical impact of genetic disorders of
bone. Diseases such as osteogenesis imperfecta, skeletal dys-
plasias, hypophosphatemia, MEN 1, MEN 2, and disorders of
the calcium sensor receptor producing hypo- and hyper-cal-
cemia. The diagnostic tools such as mutational analysis have
assisted the physician in guidance of treatment (eg, DNA diag-
nosis for prophylactic thyroidectomy in MEN 2).
Sessions 5 and 6 were devoted to new drugs for the treatment
of osteoporosis. 
The data of the bisphosphonates used in extended dosing in-
tervals were discussed. The binding affinities and potency in
relation to inhibition of key enzymes in the mevalonic acid path-
way was shown for zoledronic acid. The relationship to os-
teonecrosis of the jaw in the clinical trials was also discussed.
Ibandronate results from the compliance trials were presented
and the implications for monthly versus weekly administration
debated. The protocol for the head to head trial (MOTION) of
alendronate versus ibandronate was also shown.
The inhibition of the RANK-RANKL/OPG pathway has been uti-
lized to develop drugs which inhibit RANKL in order to sup-
press bone turnover and bone resorption. Denosumab (Amgen
162; RANKL monoclonal antibody given every 6 months by sc
injection) has successfully completed phase 2 studies and
shown impressive gains in BMD at all sites. Phase 3 fracture
trials are ongoing. 
The holy grail in terms of treating osteoporosis for Vitamin D
has been to develop specific bone sparing or forming analogs
which do not produce bone resorption and hypercalcemia.
The vitamin D receptor is the target of many initiatives to try
and fulfill this role. The vitamin D knockout models have been
used to try and explain all the actions of vitamin D but as yet
there are still many unanswered questions especially at the
molecular level. New analogs such as ED 71,2 MD and MV2
are currently being investigated for their treatment in osteo-
porosis. The results of the new SERM-bazedoxifene from
phase 2 and 3 studies were shown with the emphasis on
uterine sparing properties while preserving BMD. Anabolic
therapies such as PTH 1-34 and 1-84 were discussed in rela-
tion to fracture reduction and combination therapy with either
estrogens, raloxifene and bisphophonates. Other osteogenic
peptides such as hPTH 1-31 and PTHrP 1-36, nasal oral and
dermal preparations were mentioned as potential therapeutic
options.
Strontium ranelate is not approved in the USA for the treatment
of osteoporosis but is used in other countries. The data on frac-
ture reduction from the pivotal trials, pharmacokinetic and phar-
macodynamic data on this drug was presented. The last talk of
this session was a presentation of the development of small
molecules such as alpha V beta integrin, and cathepsin K to in-
hibit bone resorption. Knockout animal models which develop
osteosclerosis led to exploration of the potential of these com-
pounds for treating humans with osteoporosis. Cathepsin K in-
hibition produces bone resorption inhibition in animal models
whilst sparing bone formation. Human studies are ongoing with
cathepsin K and preliminary results show significant reduction
of markers of bone resorption and little or no change in forma-
tion markers.
The meeting concluded after this talk.
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